Fennec Pharmaceuticals (TSE:FRX) Lifted to Overweight at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Fennec Pharmaceuticals (TSE:FRXGet Rating) from a neutral rating to an overweight rating in a report released on Tuesday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Fennec Pharmaceuticals’ FY2022 earnings at ($1.23) EPS and FY2023 earnings at ($1.05) EPS.

Other analysts also recently issued research reports about the stock. Capital One Financial reaffirmed an overweight rating on shares of Fennec Pharmaceuticals in a report on Wednesday, September 7th. HC Wainwright reaffirmed a buy rating on shares of Fennec Pharmaceuticals in a report on Thursday, October 20th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of Buy and an average price target of C$10.00.

Fennec Pharmaceuticals Stock Performance

Shares of FRX opened at C$12.80 on Tuesday. The company has a market cap of C$335.85 million and a PE ratio of -15.65. The company has a debt-to-equity ratio of 881.09, a current ratio of 10.30 and a quick ratio of 10.17. The firm has a 50-day moving average of C$11.04 and a 200-day moving average of C$9.11. Fennec Pharmaceuticals has a one year low of C$4.95 and a one year high of C$13.25.

Insiders Place Their Bets

In other Fennec Pharmaceuticals news, Senior Officer Robert Christopher Andrade sold 19,052 shares of Fennec Pharmaceuticals stock in a transaction dated Wednesday, September 21st. The shares were sold at an average price of C$11.02, for a total value of C$209,888.26. Following the completion of the sale, the insider now owns 176,721 shares in the company, valued at approximately C$1,946,864.57. Insiders sold 38,119 shares of company stock worth $250,942 in the last quarter.

Fennec Pharmaceuticals Company Profile

(Get Rating)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014.

Featured Articles

Analyst Recommendations for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.